FDA Clears Transit Scientific's XO Cross Catheters for Coronary Use

Patrice Wendling

April 12, 2022

Transit Scientific announced US Food and Drug Administration (FDA) 510(k) clearance of its XO Cross Support Catheter platform to include coronary use.

The platform is indicated to guide and support guidewire access, allow guidewire exchanges, and deliver saline or contrast agents during coronary or peripheral vascular interventions.

Transit Scientific will launch the 2-F coronary XO Cross 14 microcatheter for use with standard 0.014-inch guidewires in 90-, 135-, 150-, and 175-cm working lengths. The nontapered shaft and tapered polymer tip offer a low crossing profile and facilitate coaxial use through any 035-compatible coronary guiding catheter, the company stated in a news release.

The XO Cross platform is designed to deliver greater pushability, trackability, flexibility, and torque response for access in challenging lesions and tortuosity, it said.

Transit Scientific reported receiving FDA 510(k) clearance in November 2021 for 12 new hydrophilic-coated XO Cross microcatheters for use in the peripheral vasculature.

Follow Patrice Wendling on Twitter: @pwendl For more from theheart.org | Medscape Cardiology, follow us on Twitter and Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.